Yoon In-ho, the eldest son of Yoon Do-joon, chairman of Dongwha Pharm, has been promoted to president and CEO.
Dongwha Pharm announced on the 26th that Yoon In-ho was promoted to president and CEO during a board meeting held after the shareholders' meeting. Accordingly, Dongwha Pharm changed to a dual CEO system with Yu Jun-ha and Yoon In-ho. This marks the full-scale management of the fourth generation of owners following the late founder Yoon Chang-sik and the late honorary chairman Yoon Kwang-yeol, along with chairman Yoon Do-joon.
Yoon In-ho joined Dongwha Pharm's finance department in August 2013. After working in key departments such as strategic planning, health and wellness business, and OTC general business for 12 years, he most recently served as COO (Chief Operating Officer) of Dongwha Pharm and as CEO of DWP Holdings.
Yoon noted, "As the longest-standing pharmaceutical company in the country, we will do our best to diversify our business and advance into a global healthcare corporation based on the capabilities and trust we have built, as well as the industry-leading principles of fair transaction and ethical management."
Meanwhile, Dongwha Pharm's main products include digestive medicine Hwalmyungsoo, skin ointment Fusidin, and cold medicine Pankol.